Loretta Nastoupil, MD

Loretta J. Nastoupil, MD, discusses the safety and efficacy data from the phase 2 TRANSCEND FL trial evaluating lisocabtagene maraleucel in patients with relapsed/refractory follicular lymphoma.

OncLive speaks with Dr. Loretta Nastoupil on some exciting non-Hodgkin lymphoma studies and Dr. Michael Pulsipher on some intriguing pediatric cancer research.

Loretta J. Nastoupil, MD, discusses logistical considerations for CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

Loretta J. Nastoupil, MD, discusses challenges faced with CAR T-cell therapy in patients with diffuse large B-cell lymphoma.

The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.